Dimerix Secures US$30 Million Initial Payment from Amicus for DMX-200 Licensing

Dimerix Limited ( (AU:DXB) ) has provided an update.

Dimerix Limited has received an initial payment of US$30 million from Amicus Therapeutics as part of a licensing agreement for the commercialization of DMX-200 in the United States. This agreement, along with others, positions Dimerix to potentially earn up to AU$1.4 billion in upfront and milestone payments, plus royalties, significantly enhancing its financial and operational capabilities to advance DMX-200 as a treatment for FSGS. The company retains rights to DMX-200 in territories not covered by existing agreements and continues to seek additional licensing opportunities.

More about Dimerix Limited

Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, including kidney and respiratory diseases. The company is advancing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease, utilizing its Receptor Heteromer Investigation Technology (Receptor-HIT) platform.

YTD Price Performance: 122.06%

Average Trading Volume: 2,573,470

Technical Sentiment Signal: Sell

Current Market Cap: A$422.8M

See more insights into DXB stock on TipRanks’ Stock Analysis page.